- Home
- INMD vs SGP Comparison
INMD vs SGP Comparison
Compare INMD & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMD | SGP |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.0M | 932.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | INMD | SGP |
|---|---|---|
| Price | $12.76 | $26.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $16.75 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 832.3K | 89.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.70 | N/A |
| Revenue Next Year | $3.99 | N/A |
| P/E Ratio | $10.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.95 | $24.71 |
| 52 Week High | $19.09 | $30.56 |
Technical Indicators
Market Signals| Indicator | INMD | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 29.67 | 51.23 |
| Support Level | N/A | $25.38 |
| Resistance Level | $14.80 | $30.02 |
| Average True Range (ATR) | 0.27 | 1.62 |
| MACD | -0.10 | -0.20 |
| Stochastic Oscillator | 0.31 | 31.78 |
Price Performance
Historical ComparisonAbout INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.